Inhibition of Middle East Respiratory Syndrome Coronavirus Infection by Anti-CD26 Monoclonal Antibody

K Ohnuma, Bart Haagmans, R Hatano, Stalinraj Victor, H Mou, S Iwata, NH Dang, BJ (Berend Jan) Bosch, C Morimoto

Research output: Contribution to journalArticleAcademicpeer-review

83 Citations (Scopus)


We identified the domains of CD26 involved in the binding of Middle East respiratory syndrome coronavirus (MERS-CoV) using distinct clones of anti-CD26 monoclonal antibodies (MAbs). One clone, named 2F9, almost completely inhibited viral entry. The humanized anti-CD26 MAb YS110 also significantly inhibited infection. These findings indicate that both 2F9 and YS110 are potential therapeutic agents for MERS-CoV infection. YS110, in particular, is a good candidate for immediate testing as a therapeutic modality for MERS.
Original languageUndefined/Unknown
Pages (from-to)13892-13899
Number of pages8
JournalJournal of Virology
Issue number24
Publication statusPublished - 2013

Research programs

  • EMC MM-04-27-01

Cite this